Abstract 229: Real-world hsCRP Testing, With a Potential to Evaluate Residual Inflammatory Cardiovascular Risk, Among Patients With History of Myocardial Infarction in the United States: A Retrospective Database Analysis
Background: C-reactive protein can be measured by a high-sensitivity assay (hsCRP) to detect persistent low grade vascular inflammation predictive of cardiovascular (CV) risk in patients with history of myocardial infarction (MI). However, the real-world use of hsCRP testing among patient with history of MI, and hence the contemporary usage to address residual inflammatory risk, is unknown
Methods: Patients with ≥1 claim with an inpatient, primary diagnosis for MI (ICD-9-CM code: 410.xx) between 01 October 2011 to 30 September 2014 (the most recent set as an index) in MarketScan and 1 year continuous enrolment pre- and post-hospital admission were included
Results: A total of 71,071 patients (mean age 63.6 years, 67.6% males) were included. The hsCRP measurement was performed in 3.3% patients (CCAE: 4.7%; Medicare: 1.3%) with a mean time of 4.3 months after the index MI; 81.7% of patients were tested ≥30 days after the index MI. Patient characteristics and resource uses were similar among hsCRP tested and non-tested patients (Table 1)
Conclusion: hsCRP testing with a potential to evaluate residual inflammatory CV risk is not used widely in routine clinical practice in US patients with history of MI. No systematic effect of hsCRP testing was observed with respect to patient characteristics and resource use. Further research is warranted to understand and describe the real-world usage of hsCRP testing to evaluate residual inflammatory risk and the associated patient characteristics, outcomes and burden of disease
Author Disclosures: C. Deschaseaux: A. Employment; Significant; Novartis Pharma AG, Basel, Switzerland. P. Sharma: A. Employment; Significant; Novartis Pharmaceuticals Corporation, NJ, US. A. Gabrielsen: A. Employment; Significant; Novartis Sverige AB,Täby, Sweden. A. Siadimas: A. Employment; Significant; Novartis Global Service Center, Dublin, Ireland. M. Bauer: A. Employment; Significant; Novartis Global Service Center, Dublin, Ireland. R. Przybysz: A. Employment; Significant; Novartis Pharmaceuticals Corporation, NJ, US.
- © 2017 by American Heart Association, Inc.